GENEDRIVE PLC — AGM Information 2016

Nov 30, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5862Q

Genedrive PLC

30 November 2016

RNS  

For release: 30 November 2016

genedrive plc ("genedrive" or the "Company")

Result of AGM

genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held in Manchester today, all resolutions proposed were duly passed.

-  Ends  -

For further details please contact:

genedrive plc

David Budd: CEO                                                                                                              +44 (0)161 989 0245

Peel Hunt LLP

James Steel                                                                                                                       +44 (0)207 418 8900

Oliver Jackson

Consilium Strategic Communications

Chris Gardner                                                                                                                    +44 (0)203 709 5700

Matthew Neal

Laura Thornton

genedrive@consilium-comms.com 

Notes to Editors

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.

genedrive plc was formerly Epistem plc and continues to provide contract research services to drug development companies under the Epistem brand name.

Further details can be found at: www.genedriveplc.com and www.genedrive.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGBSBDBSBXBGLG